PTC THERAPEUTICS, INC. 4

Michael Schmertzler, via Section Six Partners, L.P., sold a total of 20,000 shares of PTC Therapeutics, Inc. common stock in open-market transactions under a Rule 10b5-1 plan for approximately $1.35 million.

On September 9 and 10, 2026, Michael Schmertzler, a reporting person associated with PTC Therapeutics, Inc., reported open-market sales of PTC common stock held indirectly through Section Six Partners, L.P. pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2026. The transactions consisted of three separate sale tranches totaling 20,000 shares at weighted-average prices ranging from approximately $67.34 to $68.67 per share, for aggregate proceeds of about $1.35 million. Following these sales, indirect holdings reported as beneficially owned were reduced to 1,316,594 shares, with Schmertzler disclaiming beneficial ownership beyond his pecuniary interest in Section Six Partners, L.P. Based on the sale prices, the post-transaction position is worth roughly $88.7 million.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001288952-26-000008

Alert Tier

7